Equities

Alliance Pharma PLC

Alliance Pharma PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)44.50
  • Today's Change0.20 / 0.45%
  • Shares traded2.01m
  • 1 Year change+16.34%
  • Beta0.8144
Data delayed at least 20 minutes, as of Nov 21 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform4
Hold2
Sell0
Strong Sell0

Share price forecast in GBX

The 8 analysts offering 12 month price targets for Alliance Pharma plc have a median target of 67.50, with a high estimate of 85.00 and a low estimate of 42.00. The median estimate represents a 51.69% increase from the last price of 44.50.
High91.0%85.00
Med51.7%67.50
Low-5.6%42.00

Earnings history & estimates in GBX

Alliance Pharma plc reported annual 2023 earnings of 4.54 per share on Jun 19, 2024.
Average growth rate+0.01%
More ▼

Revenue history & estimates in GBP

Alliance Pharma plc had revenues for the full year 2023 of 180.68m. This was 7.92% above the prior year's results.
Average growth rate+7.98%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.